Recipharm Adds Sterile Cream and Ointment Line at Portugal Site

COMPANY PROFILE
  • Recipharm has introduced a new sterile cream and ointment manufacturing line at its Odivelas site in Portugal, expanding its sterile semi-solid production capacity.
  • The line fills aluminum and polyfoil tubes from 3.5 g to 30 g, with annual output of 8 million to 15 million units, depending on batch size and fill volume.

Recipharm, a global contract development and manufacturing organization (CDMO), has introduced a new sterile cream and ointment manufacturing line at its Odivelas facility in Portugal. The line supports a range of sterile applications, including ophthalmics, and is ready to accommodate new customer projects.

The investment expands Recipharm’s sterile semi-solid manufacturing capacity and gives pharmaceutical companies more options for product formats and batch sizes. The Odivelas site combines dedicated sterile cream and ointment capacity with an existing sterile ophthalmic line, allowing customers to source a broader range of sterile products from one facility under a single quality system.

The new line fills aluminum and polyfoil tubes in sizes ranging from 3.5 g to 30 g. Its annual output ranges from 8 million to 15 million units, depending on batch size and fill volume. The facility provides the controlled environment and manufacturing expertise required for sterile products.

“Sterile manufacturing is one of Recipharm’s core strengths. The new line would give customers more capacity and format options without adding complexity to their supply chains.”

Greg Behar, CEO of Recipharm

The investment strengthens Recipharm’s sterile semi-solid manufacturing offering at Odivelas. The company said the new line and existing multidose ophthalmic line enable customers to access a wider range of sterile products using the same site, quality system and teams.

EXCLUSIVE DOWNLOAD

Download the full CDMO Live Report for 112 pages of insights and best practices in external manufacturing.